Evonik launches EUDRAGIT® FL 30 D-55, an advanced combination polymer that sets a new benchmark for enteric coatings
Highly-flexible polymer enabling plasticizer-free formulations
New proprietary manufacturing technology combines the benefits of two pharmacopoeial polymers
Easy-to-process, with spray suspension preparation times reduced by up to 70%
Thin films allow for increased drug loads with multiparticulates
Evonik, a global leader for functional excipients used in oral solid dosage forms, today announced the launch of an advanced combination polymer for enteric coatings.
EUDRAGIT® FL 30 D-55 leverages Evonik’s new, proprietary AEMP® technology (Advanced Excipient Manufacturing Process) to combine the respective benefits of two well-established and monographed polymers including EUDRAGIT® L 30 D-55.
EUDRAGIT® FL 30 D-55 is a highly flexible polymer that enables plasticizer-free formulations, making it ideal for the compression of coated multiparticulates. It can be sprayed with a smooth, fast and no-stick process for excellent adhesion. As a single product, spray suspension preparation times can be reduced by up to 70%, while lowering manufacturing costs and total required polymer volumes. It has also been shown to reduce coating film thicknesses, creating opportunities for increased drug loading.
“As the first ever excipient based upon our proprietary AEMP® technology, EUDRAGIT® FL 30 D-55 combines the best features of two well-accepted polymers including EUDRAGIT® L 30 D-55, which has been the gold standard for enteric coatings for decades,” said Paul Spencer, Global Head of Oral Drug Delivery Solutions for the Health Care business line of Evonik. “This high-tech excipient features extremely high flexibility even without plasticizers. EUDRAGIT® FL 30 D-55 sets a new standard for enteric coatings to help customers reduce processing complexity, lower preparation times and save costs.”
Companies seeking more information about EUDRAGIT®
FL 30 D-55 can visit the Evonik booth 9K20 at CPhI Worldwide in Madrid from October 9 to 11, or AAPS PharmSci 360 in Washington D.C. from November 4 to 7 at booth 2127. Requests for individual meetings or product samples can be made via firstname.lastname@example.org.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.5 billion in 2017.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.